Tags

Type your tag names separated by a space and hit enter

Exhaled leukotrienes and prostaglandins in COPD.
Thorax. 2003 Jul; 58(7):585-8.T

Abstract

BACKGROUND

The role of eicosanoids, including leukotrienes (LTs) and prostaglandins (PGs), in chronic obstructive pulmonary disease (COPD) is uncertain. The aim of this study was to investigate whether eicosanoids are measurable in exhaled breath condensate (EBC), a non-invasive method of collecting airway secretions, in patients with stable mild to moderate COPD, and to show possible differences in their concentrations compared with control subjects.

METHODS

LTB(4), LTE(4), PGE(2), PGD(2)-methoxime, PGF(2alpha), and thromboxane B(2) (TxB(2)) were measured in EBC in 15 healthy ex-smokers, 20 steroid naïve patients with COPD who were ex-smokers, and in 25 patients with COPD who were ex-smokers and who were treated with inhaled corticosteroids. The study was of cross sectional design and all subjects were matched for age and smoking habit.

RESULTS

LTB(4) and PGE(2) concentrations were increased in steroid naïve (LTB(4): median 100.6 (range 73.5-145.0) pg/ml, p<0.001; PGE(2): 98.0 (range 57.0-128.4) pg/ml, p<0.001) and steroid treated patients with COPD (LTB(4): 99.0 (range 57.9-170.5) pg/ml, p<0.001; PGE(2): 93.6 (range 52.8-157.0) pg/ml, p<0.001) compared with control subjects (LTB(4): 38.1 (range 31.2-53.6) pg/ml; PGE(2): 44.3 (range 30.2-52.1) pg/ml). Both groups of patients had similar concentrations of exhaled LTB(4) (p=0.43) and PGE(2) (p=0.59). When measurable, LTE(4) and PGD(2)-methoxime concentrations were similar in COPD patients and controls, whereas PGF(2alpha) concentrations were increased in the former. TxB(2)-LI was undetectable in any of the subjects.

CONCLUSIONS

There is a selective increase in exhaled LTB(4) and PGE(2) in patients with COPD which may be relatively resistant to inhaled corticosteroid therapy.

Links

Publisher Full Text
ncbi.nlm.nih.gov
thorax.bmj.com
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Montuschi P
Department of Pharmacology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. pmontuschi@rm.unicatt.it
Kharitonov SA
No affiliation info available
Ciabattoni G
No affiliation info available
Barnes PJ
No affiliation info available

MeSH

Administration, InhalationAdrenal Cortex HormonesAgedBreath TestsCross-Sectional StudiesDinoprostDinoprostoneFemaleForced Expiratory VolumeHumansLeukotriene B4Leukotriene E4LeukotrienesMaleMiddle AgedProstaglandin D2ProstaglandinsPulmonary Disease, Chronic ObstructiveThromboxane B2Vital Capacity

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12832671

Citation

Montuschi, P, et al. "Exhaled Leukotrienes and Prostaglandins in COPD." Thorax, vol. 58, no. 7, 2003, pp. 585-8.
Montuschi P, Kharitonov SA, Ciabattoni G, et al. Exhaled leukotrienes and prostaglandins in COPD. Thorax. 2003;58(7):585-8.
Montuschi, P., Kharitonov, S. A., Ciabattoni, G., & Barnes, P. J. (2003). Exhaled leukotrienes and prostaglandins in COPD. Thorax, 58(7), 585-8.
Montuschi P, et al. Exhaled Leukotrienes and Prostaglandins in COPD. Thorax. 2003;58(7):585-8. PubMed PMID: 12832671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Exhaled leukotrienes and prostaglandins in COPD. AU - Montuschi,P, AU - Kharitonov,S A, AU - Ciabattoni,G, AU - Barnes,P J, PY - 2003/7/2/pubmed PY - 2003/8/21/medline PY - 2003/7/2/entrez SP - 585 EP - 8 JF - Thorax JO - Thorax VL - 58 IS - 7 N2 - BACKGROUND: The role of eicosanoids, including leukotrienes (LTs) and prostaglandins (PGs), in chronic obstructive pulmonary disease (COPD) is uncertain. The aim of this study was to investigate whether eicosanoids are measurable in exhaled breath condensate (EBC), a non-invasive method of collecting airway secretions, in patients with stable mild to moderate COPD, and to show possible differences in their concentrations compared with control subjects. METHODS: LTB(4), LTE(4), PGE(2), PGD(2)-methoxime, PGF(2alpha), and thromboxane B(2) (TxB(2)) were measured in EBC in 15 healthy ex-smokers, 20 steroid naïve patients with COPD who were ex-smokers, and in 25 patients with COPD who were ex-smokers and who were treated with inhaled corticosteroids. The study was of cross sectional design and all subjects were matched for age and smoking habit. RESULTS: LTB(4) and PGE(2) concentrations were increased in steroid naïve (LTB(4): median 100.6 (range 73.5-145.0) pg/ml, p<0.001; PGE(2): 98.0 (range 57.0-128.4) pg/ml, p<0.001) and steroid treated patients with COPD (LTB(4): 99.0 (range 57.9-170.5) pg/ml, p<0.001; PGE(2): 93.6 (range 52.8-157.0) pg/ml, p<0.001) compared with control subjects (LTB(4): 38.1 (range 31.2-53.6) pg/ml; PGE(2): 44.3 (range 30.2-52.1) pg/ml). Both groups of patients had similar concentrations of exhaled LTB(4) (p=0.43) and PGE(2) (p=0.59). When measurable, LTE(4) and PGD(2)-methoxime concentrations were similar in COPD patients and controls, whereas PGF(2alpha) concentrations were increased in the former. TxB(2)-LI was undetectable in any of the subjects. CONCLUSIONS: There is a selective increase in exhaled LTB(4) and PGE(2) in patients with COPD which may be relatively resistant to inhaled corticosteroid therapy. SN - 0040-6376 UR - https://www.unboundmedicine.com/medline/citation/12832671/Exhaled_leukotrienes_and_prostaglandins_in_COPD_ L2 - https://thorax.bmj.com/lookup/pmidlookup?view=long&amp;pmid=12832671 DB - PRIME DP - Unbound Medicine ER -